Saveo is a pharmacy-focused supply chain and marketplace platform that has grown 103 times since its launch. From 1.9 crore in FY20 to 196 crore in FY24, its revenue skyrocketed. In the same time frame, the business was also able to lower its losses.

Saveo's financial statement, which was obtained from the Registrar of Companies (RoC), shows that its operating revenue climbed 16.7% from 168 crore in FY23 to 196 crore in FY24.

In addition to acting as a procurement center for generics, surgical supplies, over-the-counter items, specialty medications, allopathy, and ayurvedic medicines, Saveo is a business-to-business pharmaceutical marketplace that links pharmaceutical corporations with merchants. In FY24, its only source of income was from the selling of these medications.

Regarding costs, 78% of the overall expenditures were related to the purchase of medications. From 154 crore in FY23 to 184 crore in FY24, this expense increased by 19.5%. Nonetheless, Saveo reduced employee benefit expenditures by 24.32%, or 28 crore, in the most recent fiscal year by optimizing its personnel costs.

In the previous fiscal year, other overheads, such as operational costs, totaled 16.23 crore, while finance costs rose by 40% to 7 crore. In FY24, Saveo's overall spending increased by 10% to 235 crore.

The Bengaluru-based company was able to reduce its losses from 46 crore in FY23 to 38.5 crore in FY24, a 16% decrease. Its EBITDA margin and ROCE both increased to -15.69% and -225%, respectively.

Saveo improved from 1.27 in FY23 to 1.20 in FY24, spending 1.20 on every rupee of revenue. For FY24, the company declared current assets of 57 crore, which included 10 crore in cash and bank balance.

To date, Saveo has raised $20 million in funding, according to TheKredible, a startup data intelligence platform. Matrix Partners (11.81%), RTP Global Partners (10.42%), and Indian Quotient (9.06%) are among its top investors.